Skip to main content

Use of nimotuzumab combined with cisplatin in treatment of nasopharyngeal carcinoma and its effect on expressions of VEGF and MMP-2



This paper aims to observe the expressions of VEGF and MMP-2 in patients with nasopharyngeal carcinoma treated by nimotuzumab combined with cisplatin.


Altogether, 104 patients with nasopharyngeal carcinoma treated in our hospital from April 2014 to August 2016 were selected as research subjects. Among them, 50 patients treated with cisplatin were divided into a control group and 54 patients treated with nimotuzumab combined with cisplatin were divided into an observation group. The two groups of patients were compared in terms of efficacy after treatment and incidence of adverse reactions. Changes of serum VEGF and MMP-2 concentrations before and after treatment were detected using enzyme-linked immunosorbent assay (ELISA), and the 3-year overall survival (OS) of patients was observed.


Compared with the control group, patients in the observation group had significantly higher total remission rate (RR) (P < 0.05) and significantly lower incidence of adverse reactions (P < 0.05). Before treatment, there was no significant difference between the observation and control groups in the concentrations of VEGF and MMP-2 (P > 0.05). After treatment, the concentrations in the two groups were significantly lower than those before treatment (P < 0.05), and the concentrations in the observation group were significantly lower than those in the control group (P < 0.05). There was no significant difference in the 3-year OS between the observation and control groups (P > 0.05).


Nimotuzumab combined with cisplatin could improve the conditions of patients with nasopharyngeal carcinoma. After treatment, the expression of VEGF and MMP-2 decreased significantly. We speculated that it improves the survival rate of patients by reducing the expression of VEGF and MMP-2.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2


  1. Paul P, Deka H, Malakar AK, Halder B, Chakraborty S. Nasopharyngeal carcinoma: understanding its molecular biology at a fine scale. Eur J Cancer Prev. 2018;27:33–41.

    CAS  Article  Google Scholar 

  2. Bruce JP, Yip K, Bratman SV, Ito E, Liu FF. Nasopharyngeal cancer: molecular landscape. J Clin Oncol. 2015;33:3346–55.

    CAS  Article  Google Scholar 

  3. Shayah A, Wickstone L, Kershaw E, Agada F. The role of cross-sectional imaging in suspected nasopharyngeal carcinoma. Ann R Coll Surg Engl. 2019;101:325–7.

    CAS  Article  Google Scholar 

  4. Kourelis K, Stergiou T, Papadas A, Kourelis T, Petta E, Papadas T. Clinicopathologic idiosyncrasies of nasopharyngeal cancer in a moderate-risk Mediterranean region. Acta Otorhinolaryngol Ita. 2017;37:180–7.

    CAS  Article  Google Scholar 

  5. Liu H, Yang W, Gao H, Jiang T, Bengxin Gu, Dong Q, Wenhong Xu, Shixiu Wu, Sun X. Nimotuzumab abrogates acquired radioresistance of KYSE-150R esophageal cancer cells by inhibiting EGFR signaling and cellular DNA repair. Onco Targets Ther. 2015;8:509–18.

    Article  Google Scholar 

  6. Mazorra Z, Chao L, Lavastida A, Sanchez B, Ramos M, Iznaga N, Crombet T. Nimotuzumab: beyond the EGFR signaling cascade inhibition. Semin Oncol. 2018;45:18–26.

    CAS  Article  Google Scholar 

  7. Rawat S, Tandan H, Patel S, Chaudhari S. Safety and efficacy of nimotuzumab with concurrent chemoradiotherapy in unresectable locally advanced squamous cell carcinoma of head and neck: an Indian rural hospital experience. South Asian J Cancer. 2019;8:52–6.

    Article  Google Scholar 

  8. Westphal M, Heese O, Steinbach JP, Schnell O, Schackert G, Mehdorn M, Schulz D, Simon M, Schlegel U, et al. A randomised, open label phase III trial with nimotuzumab, an anti-epidermal growth factor receptor monoclonal antibody in the treatment of newly diagnosed adult glioblastoma. Eur J Cancer. 2015;51:522–32.

    CAS  Article  Google Scholar 

  9. Xiong H, Cheng J, Jiang S, Wen J, Jian Y, Wei L, Zhe Z, Fu-Qiang J, Peng X. The antitumor effect of resveratrol on nasopharyngeal carcinoma cells. Front Biosci (Landmark Ed). 2019;24:961–70.

    CAS  Article  Google Scholar 

  10. Takahashi S, Nakano K, Yokota T, Shitara K, Muro K, Sunaga Y, Ecstein-Fraisse E, Ura T. Phase 1 study of ombrabulin in combination with cisplatin (CDDP) in Japanese patients with advanced solid tumors. Jpn J Clin Oncol. 2016;46:1000–7.

    Article  Google Scholar 

  11. Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol. 2014;740:364–78.

    CAS  Article  Google Scholar 

  12. OuYang PY, Zhang XM, Qiu XS, Liu ZQ, Lu L, Gao YH, Xie FY. A pairwise meta-analysis of induction chemotherapy in nasopharyngeal carcinoma. Oncologist. 2019;24:505–12.

    CAS  Article  Google Scholar 

  13. Khan IS, Loh KS, Petersson F. Amyloid and hyaline globules in undifferentiated nasopharyngeal carcinoma. Ann Diagn Pathol. 2019;40:1–6.

    Article  Google Scholar 

  14. Mahecha AM, Wang H. The influence of vascular endothelial growth factor-A and matrix metalloproteinase-2 and-9 in angiogenesis, metastasis, and prognosis of endometrial cancer. OncoTargets Therapy. 2017;10:4617.

    Article  Google Scholar 

  15. Jabłońska-Trypuć A, Matejczyk M, Rosochacki S. Matrix metalloproteinases (MMPs), the main extracellular matrix (ECM) enzymes in collagen degradation, as a target for anticancer drugs. J Enzyme Inhib Med Chem. 2016;31:177–83.

    Article  Google Scholar 

  16. Kesanakurti D, Chetty C, Dinh DH, et al. Role of MMP-2 in the regulation of IL-6/Stat3 survival signaling via interaction with α5β1 integrin in glioma. Oncogene. 2013;32:327–40.

    CAS  Article  Google Scholar 

  17. Benoit T, Keller EX, Wolfsgruber P, Hermanns T, Günthart M, Banzola I, Sulser T, Provenzano M, Poyet C. High VEGF-D and low MMP-2 serum levels predict nodal-positive disease in invasive bladder cancer. Med Sci Monit. 2015;21:2266–74.

    CAS  Article  Google Scholar 

  18. Park JY, Park DH, Jeon Y, et al. Eupatilin inhibits angiogenesis-mediated human hepatocellular metastasis by reducing MMP-2 and VEGF signaling. Bioorg Med Chem Lett. 2018;28:3150–4.

    CAS  Article  Google Scholar 

  19. Stelow EB, Wenig BM. Update from the 4th edition of the World Health Organization classification of head and neck tumours: nasopharynx. Head Neck Pathol. 2017;11:16–22.

    Article  Google Scholar 

  20. Sun Y, Li WF, Chen NY, Zhang N, Hu GQ, Xie FY, Sun Y, Chen XZ, Li JG, et al. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial. Lancet Oncol. 2016;17:1509–20.

    CAS  Article  Google Scholar 

  21. Peng H, Chen L, Zhang J, Li WF, Mao YP, Zhang Y, Liu LZ, Tian L, Lin AH, et al. Induction chemotherapy improved long-term outcomes of patients with locoregionally advanced nasopharyngeal carcinoma: a propensity matched analysis of 5-year survival outcomes in the era of intensity-modulated radiotherapy. J Cancer. 2017;8:371–7.

    CAS  Article  Google Scholar 

  22. Ito T, Majima H, Ozawa T, Maeda M, Iwamoto S, Hirayama M, Azuma E. An unusual presentation of nasopharyngeal carcinoma as lemierre syndrome. Am J Case Rep. 2019;20:263–7.

    Article  Google Scholar 

  23. Hu J, Lieb JD, Sancar A, Adar S. Cisplatin DNA damage and repair maps of the human genome at single-nucleotide resolution. Proc Natl Acad Sci USA. 2016;113:11507–12.

    CAS  Article  Google Scholar 

  24. Liu ZG, Zhao Y, Tang J, Zhou YJ, Yang WJ, Qiu YF, Wang H. Nimotuzumab combined with concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma: a retrospective analysis. Oncotarget. 2016;7:24429–35.

    Article  Google Scholar 

  25. Guo J, You H, Li D. Baicalein exerts anticancer effect in nasopharyngeal carcinoma in vitro and in vivo. Oncol Res. 2019;27:601–11.

    Article  Google Scholar 

  26. Perri F, Della Vittoria Scarpati G, Caponigro F, Ionna F, Longo F, Buonopane S, Muto P, Di Marzo M, Pisconti S, et al. Management of recurrent nasopharyngeal carcinoma: current perspectives. Onco Targets Ther. 2019;12:1583–91.

    CAS  Article  Google Scholar 

  27. He W, Zou C, Tian Z, Tan W, Shen W, Chen J, Liu L, Xu R. Nasopharyngeal carcinoma treated with bevacizumab combined with paclitaxel liposome plus cisplatin: a case report and literature review. Onco Targets Ther. 2016;10:67–72.

    Article  Google Scholar 

  28. Weng C, Chen Y, Wu Y, Liu X, Mao H, Fang X, Li B, Wang L, Guan M, et al. Silencing UBE4B induces nasopharyngeal carcinoma apoptosis through the activation of caspase3 and p53. Onco Targets Ther. 2019;12:2553–61.

    CAS  Article  Google Scholar 

  29. Wells JM, Gaggar A, Blalock JE. MMP generated matrikines. Matrix Biol. 2015;44–46:122–9.

    Article  Google Scholar 

  30. Chen WH, Luo GF, Lei Q, Jia HZ, Hong S, Wang QR, Zhuo RX, Zhang XZ. MMP-2 responsive polymeric micelles for cancer-targeted intracellular drug delivery. Chem Commun (Camb). 2014;51:465–8.

    Article  Google Scholar 

  31. Shen J, Sun C, Zhou M, Zhang Z. Combination treatment with cetuximab in advanced nasopharyngeal carcinoma patients: a meta-analysis. Onco Targets Ther. 2019;12:2477–94.

    CAS  Article  Google Scholar 

  32. Lan R, Huang F, Zhong G, Chen R, Wang Z, Chen J, Fu L, Hong J, Zhang L. Effects of CKMT1 on radiosensitivity of nasopharyngeal carcinoma cells. Int J Radiat Biol. 2019;95:597–606.

    CAS  Article  Google Scholar 

Download references

Author information

Authors and Affiliations



LQ designed the study and drafted the manuscript. JW and JD were responsible for the collection and analysis of the experimental data. PK, XN and LY revised the manuscript critically for important intellectual content. All authors read and approved the final manuscript.

Corresponding author

Correspondence to L. Z. Yin.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

The study was approved by Ethical Committee of Yantaishan Hospital and conducted in accordance with the ethical standards.

Informed consent


Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Qu, L., Wang, J.H., Du, J.X. et al. Use of nimotuzumab combined with cisplatin in treatment of nasopharyngeal carcinoma and its effect on expressions of VEGF and MMP-2. Clin Transl Oncol 23, 1342–1349 (2021).

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:


  • Nimotuzumab
  • Cisplatin
  • Combined treatment
  • Nasopharyngeal carcinoma
  • VEGF
  • MMP-2